Home > Rheumatology > EULAR 2020 > Psoriatic Arthritis > Secukinumab monotherapy as efficient as adalimumab

Secukinumab monotherapy as efficient as adalimumab

Presented By
Prof. Iain McInnes, University of Glasgow, United Kingdom
Conference
EULAR 2020
Trial
Phase 3, EXCEED
Main trial data from the head-to-head EXCEED trial showed that secukinumab monotherapy for biologic-naïve patients with active psoriatic arthritis is at least as efficacious as adalimumab monotherapy  and provides higher responses on skin endpoints [1,3]. The EXCEED trial was a phase 3b study of patients with active psoriatic arthritis and an inadequate response or intolerance to conventional disease-modifying anti-rheumatic drugs (DMARDs). The trial compared the efficacy and safety of secukinumab and adalimumab as first-line biologic monotherapy through 52 weeks, with a musculoskeletal primary endpoint. The results were presented by Prof. Iain McInnes (University of Glasgow, United Kingdom), and simultaneously published in The Lancet [1,2]. Participants (n=853) were randomised to secukinumab 300 mg/week at weeks 0-...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on